Universe Pharmaceuticals

UPC

Drug Manufacturers - Specialty & Generic · Healthcare

Exchange

NASDAQ Global Market

Winston Score

Winston is worried

Weak fundamentals across most pillars.

Data as of Aug 23, 2026 · filings through Mar 31, 2026

How the score breaks down

Quality

Weak

Growth

Weak

Cash Flow

Weak

Stability

Good

Valuation

Data not available

Track this stock — start free trial

Winston Score History

The full picture

Universe Pharmaceuticals Inc. is a small Chinese pharmaceutical company that makes and sells traditional Chinese medicine (TCM) products. Its medicines are mainly designed for older patients and focus on conditions common in aging populations, such as pain, bone health, and circulation issues. The company sells its products primarily in China through hospitals, pharmacies, and distributors.

Universe Pharmaceuticals earns money by manufacturing and selling its TCM products directly to healthcare channels across China. It is a very small company with a market cap near zero, which signals significant financial stress. The company is currently losing money at the operating level, meaning it spends more running the business than it earns, and its negative return on capital raises concerns about long-term viability. The key risk facing the business is its ability to scale revenue and reach profitability in a crowded Chinese pharmaceutical market where larger, better-funded competitors dominate distribution and brand recognition.

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

-1.3% YoY

YoY Growth Rate

Revenue declining

EPS Growth

+99.7% YoY

YoY Growth Rate

EPS growth accelerating

Insider Activity

22.9%ownership

→ Flat

Insider ownership roughly steady over the past year

Cash Runway

~19 months

$30M cash & investments

Quarterly Free Cash Flow

↓ Burn rate worsening

Adequate runway but may need to raise capital within 2 years

Revenue declining

Universe Pharmaceuticals's revenue is actually shrinking. In a growth stock, that removes the core investment thesis. The low Winston Score here may be warranted — unless there's a turnaround story.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale

Gross Margin

35.7%

Modest — 35.7% gross margin

Profit after running costs

Operating Margin

-16.6%

Losing money on operations — -16.6%

Return on the money invested

ROCE

-3.2%

Weak — -3.2% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth

Sales YoY

-8.0%

Shrinking sales (-8.0% YoY)

Profit growth

EPS YoY

N/A

Data not available

How steady the profit is

EPS Consistency

4/8 quarters

Earnings inconsistent quarter-to-quarter

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash

Cash Conversion

N/A

Data not available

Spare cash per sale

FCF Margin

-69.8%

Burning cash (-69.8%)

Free cash flow is negative. They are burning cash, not generating it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns

Debt / Equity

0.17

Conservative — low debt load (0.17)

Covers its interest

Interest Cover

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit

P/E Ratio (TTM)

N/M

no trend

Negative earnings — P/E not meaningful

Cheaper or dearer next year

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial